Work

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA ‐ CKD and FIGARO ‐ DKD

Year: 2025

Type: article

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70193

Authors: Mark André de la Rambelje, Adriaan A. Voors, Peter J. Greasley, Mario Berger, Hiddo J. L. Heerspink

Institutions: University Medical Center Groningen, University of Groningen, AstraZeneca (Sweden), Bayer (Germany)

Language: English

Topic: Chronic Kidney Disease and Diabetes

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,380

Funders: AstraZeneca, Bayer, European Commission, Defense Acquisition Program Administration

Award: Personalized Drug Response: IMplementation and Evaluation in CKD

OpenAlex ID: W4415118933

FWCI: 1.24

Cites: 17

Cited by: 2

Related to: